Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases
1 other identifier
observational
214
1 country
1
Brief Summary
Through the literature review , we pick out a series of forward-looking biological indicators as follows :
- 1.NGAL
- 2.Cystatin C:
- 3.Galectin-3:
- 4.Copeptin:
- 5.MR-Pro ANP:
- 6.sST2:
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 27, 2014
CompletedStudy Start
First participant enrolled
June 1, 2014
CompletedFirst Posted
Study publicly available on registry
July 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2016
CompletedResults Posted
Study results publicly available
February 25, 2020
CompletedFebruary 25, 2020
April 1, 2017
1.9 years
May 27, 2014
November 10, 2017
February 21, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Biomarker Titer of Patients With Coronary Artery Disease
The titer of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2).
6-12 months
Biomarker of Healthy Subjects(Placebo)
The relationship of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2) of healthy subjects(placebo).
6-12 months
SYNTAX(SYNergy Between Percutaneous Coronary Intervention With TAXus) for Stable Angina Receveived Coronary Angiogram
The relationship of 6 biomarkers(NGAL,Cystatin C,Galectin-3,Copeptin,MR-Pro ANP,sST2) with SYNTAX score. The SYNTAX Score is a unique tool to score complexity of coronary artery disease; there is no theoretical range existed for the SYNTAX score. Low risk:\<22; intermediate risk: 22-33, high risk:\>33
6-12 months
Study Arms (2)
stable angina, biomarker
patients with stable angina who received coronary angiography.
placebo
healthy subject
Interventions
percutaneous coronary intervention. coronary angiography.
Eligibility Criteria
patients with stable angina who received coronary angiography.
You may qualify if:
- stable angina who eligible for coronary angiography after non-invasive stress test.
You may not qualify if:
- intolerance to procedure or contarst medium.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Taipei City Hospital
Taipei, Taiwan
Biospecimen
ELISA kit for Human Galectin-3 Quantikine ELISA Kit (R\&D system, Minneapolis, Mn)、Human ST2/IL-1 R4 Quantikine ELISA Kit(R\&D system, Minneapolis, Mn)、Human Cystatin C Quantikine ELISA Kit(R\&D system, Minneapolis, Mn)、 Human Lipocalin-2/NGAL Quantikine ELISA Kit(R\&D system, Minneapolis, Mn)、Human midregional pro-atrial natriuretic peptide(MR-proANP) ELISA Kit(Cusabio, China, Cn)、Soluble ST2/IL-1R4 (HUMAN) Elisa Kit(AvisceraBioscience, Santa Clara,Ca)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- chen yueh-chung
- Organization
- taipei city hospital
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- chief of ICU
Study Record Dates
First Submitted
May 27, 2014
First Posted
July 1, 2014
Study Start
June 1, 2014
Primary Completion
May 1, 2016
Study Completion
October 1, 2016
Last Updated
February 25, 2020
Results First Posted
February 25, 2020
Record last verified: 2017-04